BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34629314)

  • 1. Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
    Sakach E; O'Regan R; Meisel J; Li X
    Clin Breast Cancer; 2021 Dec; 21(6):509-520. PubMed ID: 34629314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
    Lee A; Djamgoz MBA
    Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
    McCann KE; Hurvitz SA; McAndrew N
    Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging treatment approaches for triple-negative breast cancer.
    Capuozzo M; Celotto V; Santorsola M; Fabozzi A; Landi L; Ferrara F; Borzacchiello A; Granata V; Sabbatino F; Savarese G; Cascella M; Perri F; Ottaiano A
    Med Oncol; 2023 Dec; 41(1):5. PubMed ID: 38038783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.
    Mai N; Abuhadra N; Jhaveri K
    Clin Breast Cancer; 2023 Dec; 23(8):784-799. PubMed ID: 37336650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple negative breast cancer: any closer to cracking the code?
    Peddi PF
    Curr Opin Obstet Gynecol; 2022 Feb; 34(1):52-55. PubMed ID: 34967815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    Nagayama A; Vidula N; Bardia A
    Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
    Fremd C; Jaeger D; Schneeweiss A
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):29-42. PubMed ID: 30351981
    [No Abstract]   [Full Text] [Related]  

  • 12. Triple negative breast cancer in Asia: An insider's view.
    Wang C; Kar S; Lai X; Cai W; Arfuso F; Sethi G; Lobie PE; Goh BC; Lim LHK; Hartman M; Chan CW; Lee SC; Tan SH; Kumar AP
    Cancer Treat Rev; 2018 Jan; 62():29-38. PubMed ID: 29154023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.
    Davis AA; Gradishar WJ
    Oncology (Williston Park); 2020 May; 34(5):176-182. PubMed ID: 32644178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
    Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.